Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
The company offers drug discovery and development services to several biotech and pharmaceutical companies.Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target.
總部位於德國的Evotec SE（納斯達克:EVO）據報道正在週一交易，有報道稱該公司成爲了一家收購目標。
The private equity firm Triton Partners is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter.
據Bloomberg報道，股權投資公司Triton Partners據稱正在考慮收購Evotec，引用知情人士的話。
In an SEC filing, Evotec reported that Triton had acquired a 9.99% stake in the company via several open-market transactions.
在一份SEC文件中，Evotec報告說Triton通過幾筆公開市場交易已經收購了公司9.99%的股份。
The company offers drug discovery and development services to several biotech and pharmaceutical companies.
該公司向幾家生物技術和藥品公司提供藥物研發和開發服務。
Also Read: Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
另請參閱：諾和諾德與Evotec在幹細胞治療開發上的合作
According to the report, the investment firm has been trying to meet with senior Evotec executives as it looks into a possible buyout.
根據報告，這家投資公司一直在努力與Evotec的高管會面，以研究可能的收購事宜。
If Triton wants to increase its stake to 10% or more, it would need approval for foreign investment, the report added.
如果Triton想要增加其股權至10%或更多，根據報告，它將需要獲得外國投資的批准。
Any major move would also require backing from Evotec's key shareholders, including Novo Holdings, the parent company of Novo Nordisk A/S (NYSE:NVO), and the Abu Dhabi-based Mubadala Investment.
任何一項重大動作也將需要Evotec的主要股東的支持，包括Novo Holdings，也就是Novo Nordisk A/S（紐交所:NVO）的母公司，以及總部位於阿布扎比的Mubadala Investment。
Last week, the German company reported third-quarter revenues of 184.89 million euros, down from 196.28 million a year ago, noting a soft market in shared R&D.
上週，這家德國公司報告第三季度營收爲18489萬歐元，較一年前的19628萬歐元下降，指出合作研發市場疲軟。
It reported an operating loss of 26.46 million euros, compared to 12.19 million euros loss a year ago.
報告營運虧損爲2646萬歐元，相比一年前的1219萬歐元虧損。
In its second-quarter earnings, Evotec's CEO said the company is operating in a more challenging market environment, notably the slowdown of early-stage R&D spending.
在其第二季度收入方面，Evotec的首席執行官表示，公司正在一個更具挑戰性的市場環境中運營，特別是早期研發支出放緩。
In October, Evotec announced advancements in its strategic partnership with Bristol-Myers Squibb & Co (NYSE:BMY), which is focused on developing a molecular glue-based pipeline.
十月份，Evotec宣佈其與百時美施貴寶（紐交所：BMY）戰略合作取得進展，重點是開發基於分子粘合劑的產品線。
Price Action: EVO stock is up 16.2% at $4.80 at last check Monday.
股價走勢：EVO股價上漲16.2%，至4.80美元，最新數據顯示週一上漲。
- GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details
- GE Healthcare與DeepHealth攜手推動人工智能輔助乳腺癌篩查：詳情
譯文內容由第三人軟體翻譯。
